News articles about Exact Sciences Corporation (NASDAQ:EXAS) have trended somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Exact Sciences Corporation earned a news impact score of 0.11 on Accern’s scale. Accern also gave news headlines about the medical research company an impact score of 46.9130807407232 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the news headlines that may have impacted Accern Sentiment’s analysis:
- Even Exact Sciences Bulls Wonder If Expectations Are Lofty (finance.yahoo.com)
- Exact Sciences Corporation (EXAS) CEO Sells $8,149,787.70 in Stock (americanbankingnews.com)
- Is Exact Sciences Corporation Stock a Buy? (fool.com)
- Short Interest in Exact Sciences Corporation (EXAS) Declines By 17.9% (americanbankingnews.com)
- Technical check on Exact Sciences Corporation (EXAS) – Stocks Gallery (stocksgallery.com)
Shares of Exact Sciences Corporation (NASDAQ:EXAS) opened at $58.33 on Wednesday. The company has a quick ratio of 9.98, a current ratio of 10.34 and a debt-to-equity ratio of 0.01. Exact Sciences Corporation has a fifty-two week low of $13.05 and a fifty-two week high of $63.60.
Exact Sciences Corporation (NASDAQ:EXAS) last announced its quarterly earnings data on Monday, October 30th. The medical research company reported ($0.23) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.30) by $0.07. The firm had revenue of $72.60 million during the quarter, compared to analyst estimates of $65.03 million. Exact Sciences Corporation had a negative return on equity of 30.32% and a negative net margin of 60.71%. Exact Sciences Corporation’s quarterly revenue was up 158.4% on a year-over-year basis. During the same period in the previous year, the company earned ($0.36) earnings per share. research analysts anticipate that Exact Sciences Corporation will post -1.14 EPS for the current fiscal year.
EXAS has been the topic of several recent analyst reports. Canaccord Genuity reiterated a “buy” rating and issued a $42.00 price target (up previously from $38.00) on shares of Exact Sciences Corporation in a research note on Thursday, July 20th. Leerink Swann set a $45.00 price target on Exact Sciences Corporation and gave the stock a “buy” rating in a research note on Thursday, August 24th. Vetr upgraded Exact Sciences Corporation from a “sell” rating to a “buy” rating and set a $41.07 price target on the stock in a research note on Wednesday, August 2nd. Bank of America Corporation reiterated a “buy” rating on shares of Exact Sciences Corporation in a research note on Wednesday, July 26th. Finally, Roth Capital boosted their price target on Exact Sciences Corporation from $40.00 to $46.00 and gave the stock a “buy” rating in a research note on Wednesday, July 26th. Eight research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. Exact Sciences Corporation currently has a consensus rating of “Buy” and an average price target of $49.98.
ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Exact Sciences Corporation (EXAS) Stock Price” was originally published by Markets Daily and is the sole property of of Markets Daily. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.themarketsdaily.com/2017/11/15/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-exact-sciences-corporation-exas-stock-price.html.
In related news, Director Thomas D. Carey bought 2,500 shares of the stock in a transaction dated Thursday, August 17th. The stock was bought at an average cost of $37.71 per share, with a total value of $94,275.00. Following the completion of the acquisition, the director now owns 60,858 shares of the company’s stock, valued at $2,294,955.18. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Kevin T. Conroy sold 137,805 shares of the company’s stock in a transaction that occurred on Thursday, November 9th. The shares were sold at an average price of $59.14, for a total value of $8,149,787.70. Following the transaction, the chief executive officer now directly owns 967,867 shares of the company’s stock, valued at $57,239,654.38. The disclosure for this sale can be found here. Over the last three months, insiders sold 415,178 shares of company stock valued at $20,785,358. 4.00% of the stock is owned by corporate insiders.
About Exact Sciences Corporation
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.